Clinical Trial: Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520214) titled 'Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma' on March 24.

Brief Summary: This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.

Study Start Date: Sept. 10, 2025

Study Type: INTERVENTIONAL

Condition: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Glioblastom WHO Grade 4

Intervention: BIOLOGICAL: mRNA vaccine: GV-907、GV-108

Eligible patients will receive intradermal injections of cancer vaccines

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Bei...